8 news items
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
LLY
24 May 24
adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved clinical remission at one year, including patients with previous biologic failure
LLY
21 May 24
of mirikizumab in individuals living with this condition."
Crohn's disease is a chronic, inflammatory
Should You Hold Viking Therapeutics in Your Portfolio?
AMGN
LLY
NVO
15 May 24
in the obesity market in the long run.
Wegovy, a GLP-1 agonist, is NVO's blockbuster chronic weight management injection approved for adults
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum
LLY
30 Apr 24
, adding to the UK approval earlier in 2024, for both the type 2 diabetes and chronic weight management indications
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
LLY
17 Apr 24
GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialized
9xms2ikt3b2p8 isl1zkk1p6k
CTLT
LLY
NVO
12 Apr 24
results for semaglutide in Peripheral arterial disease (PAD) and type-2 diabetes (T2D) with chronic kidney disease (CKD)/ cardiovascular disease (CVD
k6z fjtb0pm3q700ms40khs6mm9rwapw4swp7
A
AVTR
DHR
13 Mar 24
.
According to Goldman Sachs, Eli Lilly’s tirzepatide, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight
o83hk ps5r75bt
AMGN
LLY
NVO
26 Feb 24
half of 2024.
In the inflammation and immunology (I&I) sector, Goldman Sachs says the focus lies on chronic obstructive pulmonary
- Prev
- 1
- Next